Salud financiera de hoja de balance de Jeil Pharma Holdings
Salud financiera controles de criterios 5/6
Jeil Pharma Holdings has a total shareholder equity of ₩436.3B and total debt of ₩149.4B, which brings its debt-to-equity ratio to 34.2%. Its total assets and total liabilities are ₩881.2B and ₩444.9B respectively.
Información clave
34.2%
Ratio deuda-patrimonio
₩149.39b
Deuda
Ratio de cobertura de intereses | n/a |
Efectivo | ₩48.04b |
Patrimonio | ₩436.29b |
Total pasivo | ₩444.87b |
Activos totales | ₩881.15b |
Actualizaciones recientes sobre salud financiera
These 4 Measures Indicate That Jeil Pharma Holdings (KRX:002620) Is Using Debt Extensively
Feb 27Jeil Pharma Holdings (KRX:002620) Has A Somewhat Strained Balance Sheet
Nov 23Recent updates
Is Jeil Pharma Holdings Inc (KRX:002620) A Smart Choice For Dividend Investors?
Mar 25These 4 Measures Indicate That Jeil Pharma Holdings (KRX:002620) Is Using Debt Extensively
Feb 27What Percentage Of Jeil Pharma Holdings Inc (KRX:002620) Shares Do Insiders Own?
Jan 23Jeil Pharma Holdings (KRX:002620) Has Compensated Shareholders With A 56% Return On Their Investment
Dec 28Jeil Pharma Holdings (KRX:002620) Has A Somewhat Strained Balance Sheet
Nov 23Análisis de la situación financiera
Pasivos a corto plazo: A002620's short term assets (₩387.7B) exceed its short term liabilities (₩376.7B).
Pasivo a largo plazo: A002620's short term assets (₩387.7B) exceed its long term liabilities (₩68.1B).
Historial y análisis de deuda-patrimonio
Nivel de deuda: A002620's net debt to equity ratio (23.2%) is considered satisfactory.
Reducción de la deuda: A002620's debt to equity ratio has increased from 14.3% to 34.2% over the past 5 years.
Hoja de balance
Análisis de cash runway
En el caso de las empresas que de media han sido deficitarias en el pasado, evaluamos si tienen al menos 1 año de cash runway.
Cash runway estable: A002620 has sufficient cash runway for more than 3 years based on its current free cash flow.
Pronóstico de cash runway: A002620 has sufficient cash runway for 2.6 years if free cash flow continues to grow at historical rates of 9% each year.